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event rates. Differences between NSAIDs were modeled from
observed rates of GI events and adverse effects after adjusting
for differences in population characteristics across three clinical
trials (TARGET, CLASS and VIGOR). Other enhancements
included modeling: 1) serious hepatic, renal, and skin adverse
events (AEs); 2) proton pump inhibitor use after dyspepsia, while
taking an NSAID; and 3) multiple occurrences of myocardial
infarction (MI) (as opposed to one per patient). Health state util-
ities for AEs were assigned a value equal to that for the hospi-
talized surgical management of a complicated GI event. For MI,
a 5% discount factor was used to reduce the patient’s utility
score. Patients switching to acetaminophen because of an AE can
experience reduced analgesic effect compared with NSAIDs;
therefore utilities were discounted by 20%. RESULTS: The 
modiﬁed model produced lower estimates of LYs and QALYs
(approximately 0.05 and 0.08 less, respectively) compared with
the original model which could be clinically meaningful in a 
5-year model. Patient and clinical characteristics that deﬁned 
low GI-risk subgroup versus high GI-risk group produced 
differences in LYs and QALYs of up to 1 LY and 0.7 QALY.
CONCLUSION: Effectiveness can vary considerably across
patients with varying clinical characteristics. Therefore, the cost-
effectiveness of treatment in any population should consider the
heterogeneity of patients. This model provides ﬂexible means to
compare cost-effectiveness of treatment for patients with
osteoarthritis.
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OBJECTIVES: Rituximab (RTX), a unique selective B-cell
therapy, is a new option for rheumatoid arthritis (RA) patients
who respond inadequately to anti-TNF therapies. This study
reports a cost-effectiveness analysis modelling the introduction
of RTX in Italy. METHODS: We used ACR response rates
(adjusted for differences in study populations), plus observa-
tional data from EU registries and simulated real-life treatment
for 10,000 RA patients who had responded inadequately to anti-
TNF therapy, using baseline patient characteristics from the
REFLEX study. We assumed an average treatment duration for
biological therapy (in combination with methotrexate) of up to
4.25 years over the patient’s remaining lifetime. QALYs were
mapped from a disease-severity measure (HAQ score) and based
on registry data. Relevant costs included (2004–5 Euros [€]) drug
costs (including administration and monitoring) and those
related to reduced productivity (indirect costs). We assessed RTX
as either a new treatment step or instead of adalimumab.
RESULTS: Average annual treatment costs were €8796 for RTX
+ MTX, €14,133 for adalimumab, €14,406 for etanercept, and
€9950 for inﬂiximab. Compared with the current treatment
sequence, RTX + MTX as a new treatment step produced a gain
of 0.677 QALYs at an incremental total medical cost of €12,355
over the lifetime of each patient—an incremental cost-effective-
ness ratio (ICER) of €18,259 per QALY gained. The incremen-
tal cost per QALY for drug therapy or total (direct + indirect)
cost was €19,241 and €13,621. RTX used instead of adali-
mumab produced a similar QALY gain, but resulted in a total
direct medical-cost saving of €11,389 over the patient’s lifetime.
CONCLUSIONS: RTX offers a highly acceptable incremental
cost per QALY gained for Italian patients with RA who respond
inadequately to anti-TNF therapy and the possibility of either
treating more patients within an existing budget or reducing the
overall treatment cost for RA patients.
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Rituximab (RTX), is a new and unique selective B-cell therapy
for rheumatoid arthritis (RA) patients who respond inadequately
to anti-TNF therapies. OBJECTIVES: We determined the cost-
effectiveness of introducing RTX in Spain. METHODS: Our
cost-effectiveness model simulates a real-life Spanish treatment
sequence for 10,000 RA patients who had responded inade-
quately to one anti-TNF therapy. We used ACR response rates
for RTX and current treatment options, available epidemiologi-
cal data from observational studies and baseline characteristics
from the REFLEX study. The model estimated the incremental
cost per QALY gained, with RTX as either a new or alternative
treatment over each patient’s remaining lifetime, assuming 
time-on-treatment for biological agents (in combination with
methotrexate) of up to 4.25 years. QALYs came from a disease
severity measure (HAQ score). Costs included (2004–5 EURO)
drug costs (including administration and monitoring) and costs
related to disease progression, palliative care, and reduced pro-
ductivity (indirect costs). Costs and beneﬁts were discounted at
3.5% per annum. RESULTS: Annual average treatment costs
were €7431 for RTX + MTX, €14,072 for adalimumab, €13,067
for etanercept, and €9823 for inﬂiximab. Added to existing ther-
apies, RTX would lead to a gain of 0.632 QALYs at an addi-
tional total direct medical cost of €11,550 over each patient’s
lifetime. The corresponding incremental cost-effectiveness ratio
(ICER) of RTX was €18,261 per QALY gained. Corresponding
ICERs for drug therapy and total costs were €19,597 and
€15,546 per QALY gained, respectively. Used in place of etaner-
cept as second-line biologic DMARD, RTX + MTX were 
associated with lifetime drug cost-savings of over €17,000.
CONCLUSIONS: Adding RTX to the pool of available treat-
ment options for Spanish patients with RA who respond 
inadequately to anti-TNF therapy results in a favourable 
incremental cost per QALY gained. When RTX is replacing
another biologic DMARD, the average annual drug therapy
costs can be lowered.
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OBJECTIVES: Nonsteroidal antiinﬂammatory drugs (NSAIDs)
are in widespread use for rheumatic diseases in Mexico, but can
cause peptic ulcers and gastrointestinal bleeding and perforation.
The purpose of this study was to evaluate cost—effectiveness
ratios of celecoxib compared with NSAIDs and acetaminophen
in adult patients with osteoarthritis in four hospitals in the Social
Security Mexican Institute. METHODS: A decision tree model
was developed using a Bayesian approach. The model simulated
treatment of a hypothetical cohort of 1000 patients diagnosed
with osteoarthritis during a time horizon of 6 months. Patients
could initiate treatment with celecoxib, NSAIDs (diclofenac,
naproxen) and acetaminophen. Conditional probabilities of the
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model were obtained from published clinical trials and were
complemented with Mexican expert opinion surveys. Effective-
ness measure was the number of patients with articular pain con-
trolled without adverse events (peptic ulcers, gastrointestinal
bleeding, and others). The analysis was conducted from the
healthcare payer’s perspective. Resource use and costs were
obtained from hospital records and Mexican ofﬁcial databases.
Threshold and probabilistic sensitivity analysis was performed
and acceptability curves were constructed. RESULTS: The model
indicates that the use of celecoxib could lead to the avoidance of
a signiﬁcant number of adverse events associated to NSAIDs and
acetaminophen. Celecoxib showed on the six-months period
similar (p = 0.52) expected costs per patient (US$609.8) than the
treatment with NSAIDs (US$615.6) and lower costs (p < 0.01)
compared with acetaminophen (US$656.7). On the other hand,
celecoxib was associated with higher effectiveness (371 patients,
CI 95% 255–452) followed by NSAIDs and acetaminophen (274
and 270 patients, respectively). Results were robust to Monte
Carlo ﬁrst order sensitivity analysis. Acceptability curves showed
the same results with a mean of 44.5% of certainty. CONCLU-
SIONS: Despite its higher cost in the Mexican market, celecoxib
was cost—effective for the management of articular pain in
patients with ostheoarthritis.
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OBJECTIVES: Clinical studies such as REFLEX established the
efﬁcacy of rituximab (RTX) in patients with rheumatoid arthri-
tis (RA) who have had an inadequate response to anti-TNF
therapy. This analysis evaluated the cost-effectiveness of treating
such patients with RTX across different EU countries.
METHODS: Our cost-effectiveness model assessed RA treat-
ments in a real-life setting based on practices in Germany, Italy,
Spain, France, and the UK. The model is based on ACR response
rates for RTX and current treatment options (adjusted for the
different study populations), complemented with epidemiologi-
cal data from observational studies. It simulates a cohort of
10,000 patients who have failed to respond to anti-TNF therapy.
Baseline patient characteristics were from the REFLEX study.
For each country, the cost-effectiveness of providing RTX either
as an additional treatment or an alternative to a second-line bio-
logic DMARD was examined using a treatment duration for bio-
logical therapy (in combination with methotrexate) of up to 4.25
years. QALYs were mapped from a disease severity measure
(HAQ score) and resource utilization data were UK or German
registry data. The model included costs related to drug therapy
(including administration and monitoring), palliative care and
reduced productivity (indirect costs) (2004–5 Euros [€]). Costs
and beneﬁts were discounted at 3.5% per annum. RESULTS:
Using RTX resulted in lower average annual cost compared to
any of the anti-TNF treatments. The cost per QALY (direct
medical cost) was in the range of €18,000 to €23,000 across all
health care systems. When RTX is replacing a treatment option
in the current treatment sequence, average annual treatment
costs can be reduced. CONCLUSIONS: This pan-European
analysis shows that adding RTX to the therapeutic armamen-
tarium for patients with RA who respond inadequately to anti-
TNF therapy is highly cost-effective, with an incremental cost
per QALY gained that is favourable compared to other disease-
modifying, biological therapies.
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OBJECTIVE: To perform a cost-effectiveness analysis on TNF-
alpha inhibitors (Anti-TNFa) for treatment of Ankylosing
Spondylitis (AS) in comparison to standard therapy alone from
a societal perspective. METHODS: Decision-tree analysis was
performed to estimate the incremental cost-effectiveness ratio
(ICER) for Anti-TNFa treatments in AS patients. All model para-
meters (e.g. cost, response rates, EQ-5D derived utility values,
etc.) were obtained from published literature and/or expert
opinion. Total cost included cost relating to illness, drug, drug-
related side effects, chest radiography for tuberculosis (TB)
screening, TB treatment for TB+ patients, and annual drug mon-
itoring. Cost of Illness (COI) included direct costs (e.g. total
ambulatory/hospital care, diagnostic testing, assistive devices,
travel to visits, nonallopathic treatments, etc.) and indirect costs
(e.g. short-term leave, paid work disability, etc.). Informal care-
giver cost was not included. Cost was linked to BASDAI and
BASFI scores reported in the Kobelt study by performing OLS
regression. The two resulting models (BASDAIcost and BASFIcost)
with regression equations: logCOST = 3.168 + 0.145455*BASFI
and logCOST = 3.594667 + 0.049879 * BASDAI, respectively,
were then used to estimate COI. Univariate Sensitivity Analysis
was conducted to estimate percent changes in ICER from the
base-case using parameters such as response rates, discount rates,
and discontinued rates. QALYs and cost were discounted at 3%.
RESULTS: The BASDAIcost model revealed an ICER of $46,990.
Meanwhile, the BASFIcost model had an ICER of $38,636. In the
UA analysis, the ICERs in the BASDAIcost and BASFIcost models
varied from $36,068 to $66,472 and $22,766 to $66,539,
respectively. Both models were sensitive to changes in response
rates. However, overall, the ASDAIcost model was more robust
than the BASFIcost model. CONCLUSIONS: In the UK, the
threshold level recommended by NICE for treatment was about
£30,000/QALY. This translates into US$53,589. Using the NICE
threshold, Anti-TNFa treatment for AS is cost-effective from the
societal perspective.
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OBJECTIVES: To provide a cost-efﬁcacy (CE) analysis from a
third-party payer perspective of etanercept and inﬂiximab, com-
pared to placebo in psoriatic arthritis patients. METHODS: An
Excel based CE model was developed to estimate number needed
to treat (NNT) and cost per successful outcome using published,
24-week CE data for etanercept and inﬂiximab. Dosing infor-
mation was obtained from product labels. Plan-speciﬁc drug
costs, and administration costs were utilized in the model. 
The cost of adverse events was not included in the model. The
NNT and cost per successful outcome were estimated using 
the American College of Rheumatology scores (ACR 20, 50, 70),
the Psoriasis Area and Severity Index scores (PASI 50, 75, 90),
and a combination of ACR and PASI scores. RESULTS: Based
on the ACR scores, the NNT ranges were 2.6 to 4.0 for inﬂix-
imab and 2.7 to 12.5 for etanercept. Using the PASI score, the
NNT ranges were 1.5 to 2.6 for inﬂiximab and 3.5 to 33.3 for
